| Purity: | 99 |
|---|---|
| Model Number: | 877399-52-5 |
| Brand Name: | NJBN STEROID |
| Grade Standard: | Medicine Grade |
| Type: | Vitamins, Amino Acids and Coenzymes |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 877399-52-5 |
| MF: | C21H22Cl2FN5O |
| Other Names: | Crizotinib |
| CAS No.: | 877399-52-5 |
| Sample: | Free |
| Market: | Worldwide |
Quick Details
Specifications
Factory 99% Crizotinib 877399-52-5 Potential Antitumor Agent
Product Name: Crizotinib
Synonyms: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine;(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine;Crizotinib;PF 2341066;PF-02341066;PF-2341066/Crizotinib;3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
CAS: 877399-52-5
MF: C21H22Cl2FN5O
MW: 450.343
Chemical Properties White Solid
Usage A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
Specification
Description
Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
Product Name: Crizotinib
Synonyms: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-Pyridinamine;(R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine;3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]pyridin-2-amine;Crizotinib;PF 2341066;PF-02341066;PF-2341066/Crizotinib;3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
CAS: 877399-52-5
MF: C21H22Cl2FN5O
MW: 450.343
Chemical Properties White Solid
Usage A potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). A potential antitumor agent.
Specification
|
Standard adopted |
Enterprise Standard |
|
|
Items of analysis |
Specification |
Results |
|
Appearance |
Off-White to light yellow solid |
Conforms |
|
Identification |
HPLC |
Conforms |
|
Loss on drying |
≤0.5% |
0.33% |
|
Water |
≤0.5% |
0.13% |
|
Rapid moisture |
≤0.5% |
0.32% |
|
Purity(HPLC) |
≥99.5% |
99.75% |
|
Conclusion |
Qualified |
|
Description
Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries, and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma, neuroblastoma, and other advanced solid tumors in both adults and children.
